The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
about
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Molecular classification of gastric cancer: Towards a pathway-driven targeted therapyCIViC databaseTargeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?Novel cancer chemotherapy hits by molecular topology: dual Akt and Beta-catenin inhibitorsCurrent status and perspectives of patient-derived xenograft models in cancer research.A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsClinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.Novel Non-phosphorylated Serine 9/21 GSK3β/α Antibodies: Expanding the Tools for Studying GSK3 RegulationInfluence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.Drug sensitivity testing platforms for gastric cancer diagnostics.Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.Expression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer.The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylationThe Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancerThe essential role of TNIK gene amplification in gastric cancer growthDual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
P2860
Q26775940-E19E2984-665F-4794-BDE3-935DD65F689EQ26798420-159B9A17-4187-4F66-B986-09BC076DAEEEQ27612411-8A098651-FE5D-4E3D-B7D4-A0199A1C9681Q28079596-92040535-6B1A-499A-BFEB-024E1D8B827DQ28546685-A5B4A42C-5756-4AE7-A81E-2A4C299E9F9BQ33667686-18755B6D-F8A8-4B0F-A27C-066CF0137AE8Q33764664-57CE4AAA-2E48-41BC-864A-1037BA9E0734Q33873653-F63D6669-2F5A-4196-B327-B2D6A33328AEQ34309903-29434056-5F4B-4BD3-BAB9-88867DC32FD8Q35719104-5C27E08E-88B2-4ED8-BBD4-F0B090D994AEQ36260672-63196F47-E985-43C5-8875-1B5C03408E01Q37418678-FF805A1B-00D5-4500-A879-87F5CF9576ACQ37703226-ED7BF4C8-A565-4634-8380-369279DA6EECQ38633116-860B1A21-EBE9-4317-AAF5-5912FECBA5C2Q38710557-8F77BF65-E68A-44BC-A8D7-02781A946374Q38843125-F8B73ED3-E7FB-4A44-A44A-32B4E68CF9A0Q38914271-8A24413B-B372-4A87-9057-313D2AEA5C7FQ39121571-F584F60A-A140-4A02-A8ED-3AAB46A0A5DFQ41570973-DAE30909-6B0A-4777-A3D5-4A957B214C25Q41721816-C682104E-18CE-46AC-BDCE-4FF7AED63566Q42039942-9B729629-1215-4B73-8E9E-07DC05397620Q42177839-2F90DB13-32A9-48B2-A2AE-68597D95580FQ48522177-1EDB1D35-AAC4-4EB8-9CC6-959D748CC3B8Q52654892-4EBADDBB-A624-4881-AD77-031F9A9F33AD
P2860
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@ast
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@en
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@nl
type
label
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@ast
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@en
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@nl
altLabel
The AKT inhibitor AZD5363 is s ...... del with PTEN loss to Taxotere
@en
prefLabel
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@ast
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@en
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@nl
P2093
P2860
P356
P1476
The AKT inhibitor AZD5363 is s ...... el with PTEN loss to Taxotere.
@en
P2093
Barry R Davies
Huiying Wang
Jingchuan Zhang
Minhua Zhou
Qunsheng Ji
Sufang Han
Xiaolu Yin
P2860
P2888
P356
10.1186/1479-5876-11-241
P577
2013-10-02T00:00:00Z
P5875
P6179
1033468090